Serious or severe infections caused by susceptible strains of methicillin-resistant (β-lactam-resistant) staphylococci. Staphylococcal endocarditis & enterocolitis; diphtheroid endocarditis; pseudomembranous colitis caused by C. difficile. Infections caused by staphylococci including septicaemia, bone, lower resp tract, skin & skin structure infections. Alone or in combination w/ aminoglycoside for endocarditis caused by Streptococcus viridans, S. bovis or enterococci E. faecalis.
Adult 2 g daily divided either as 500 mg every 6 hr or 1 g every 12 hr. Childn 10 mg/kg/dose every 6 hr. Neonate 1st wk of life Initially 15 mg/kg followed by 10 mg/kg every 12 hr. Infant from 1 wk-1 mth Initially 15 mg/kg followed by 10 mg/kg every 8 hr. Functional anephric patient Initially 15 mg/kg.
Not to be given as IM inj. Intraperitoneal, intrathecal (intralumbar or intraventricular) administration. Infusion-related adverse effects. Overgrowth of non-susceptible organisms; superinfection; thrombophlebitis. Perform serial monitoring of renal function & tests of auditory function during treatment. Periodically monitor leukocyte counts. Prolonged use. Concomitant use w/ anesth agents. Renal impairment. Pregnancy & lactation. Premature infants. Elderly.
Increased frequency of erythema, histamine-like flushing, anaphylactic reactions w/ anesth agents. Concurrent sequential systemic or topical use of other ototoxic &/or nephrotoxic drugs eg, aminoglycosides, amphotericin B, bacitracin, cisplatin, colistin, polymyxin B.
Sign Out
 500 mg426287d7-6259-4126-8cd8-b15501399250.GIF)
